がんバイオマーカーのグローバル市場2021~2028:オミックス技術、イメージング技術、イムノアッセイ、バイオインフォマティクス、その他

■ 英語タイトル:Global Cancer Biomarkers Market Size, Share & Industry Trends Analysis Report By Profiling Technologies, By Application, By Type, By Cancer Type, By Regional Outlook and Forecast, 2022 - 2028

調査会社KBV Research社が発行したリサーチレポート(データ管理コード:KBV22JL116)■ 発行会社/調査会社:KBV Research
■ 商品コード:KBV22JL116
■ 発行日:2022年4月
■ 調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、英国、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、マレーシア、ブラジル、アルゼンチン、UAE、サウジアラビア、南アフリカ共和国、ナイジェリア
■ 産業分野:医療
■ ページ数:325
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,600 ⇒換算¥532,800見積依頼/購入/質問フォーム
Site License(同一拠点内で共有可)USD4,320 ⇒換算¥639,360見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
KBV Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[がんバイオマーカーのグローバル市場2021~2028:オミックス技術、イメージング技術、イムノアッセイ、バイオインフォマティクス、その他]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

KBV Research社の本調査レポートでは、2021年におよそ343億ドルであった世界のがんバイオマーカー市場規模が、2022年から2028年の間に16.8%以上成長すると予測しています。本書ではがんバイオマーカーの世界市場を調査対象にし、市場範囲・手法、市場動向、市場戦略、プロファイリング技術別(オミックス技術、イメージング技術、イムノアッセイ、バイオインフォマティクス、その他)分析、用途別(診断、研究&開発、予後診断、リスク評価、その他)分析、種類別(タンパク質、遺伝子関連、その他)分析、がん種類別(乳がん、肺がん、大腸がん、甲状腺がん、その他)分析、地域別分析などを行っています。また、参入企業としてBioMérieux S.A.、F. Hoffmann-La Roche Ltd.、Becton, Dickinson and Company、Abbott Laboratories、Thermo Fisher Scientific, Inc.、Illumina, Inc.、Bio-Rad Laboratories, Inc.、Qiagen N.V.などの情報が含まれています。
・市場範囲・手法
・市場動向
・市場戦略
・世界のがんバイオマーカー市場規模:プロファイリング技術別(オミックス技術、イメージング技術、イムノアッセイ、バイオインフォマティクス、その他)
・世界のがんバイオマーカー市場規模:用途別(診断、研究&開発、予後診断、リスク評価、その他)
・世界のがんバイオマーカー市場規模:種類別(タンパク質、遺伝子関連、その他)
・世界のがんバイオマーカー市場規模:がん種類別(乳がん、肺がん、大腸がん、甲状腺がん、その他)
・世界のがんバイオマーカー市場規模:地域別(北米、ヨーロッパ、アジア太平洋、南米・中東・アフリカ)
・企業情報

The Global Cancer Biomarkers Market size is expected to reach $34.3 billion by 2028, rising at a market growth of 16.8% CAGR during the forecast period.

Cancer biomarkers are chemicals or molecules that can be traced and indicate the presence of malignant cells in the body. Cancer prevention involves diagnosing and proteins evaluating multiple cancer biomarkers using various diagnostic procedures in order to obtain timely treatment outcomes. Biomarkers include peptides, proteins, antibodies, and nucleic acids, among others. The presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicates the presence of a disease or an aberrant process. Various cancer biomarkers have been investigated and are employed as diagnostic, prognostic, personalized therapy, and surrogate endpoint biomarkers. Various businesses, like healthcare and pharmaceuticals, rely on the detection of various types of biomarkers.

One of the major factors expected to boost the cancer biomarkers market growth is research collaborations between various institutes and key industry players with the goal of developing biomarkers for disease diagnosis. For example, in May 2019, Biotech Support Group (BSG) and Leiden University Medical Center (LUMC) announced a research collaboration with the goal of developing stromal conditioning biomarkers in cancer (protein biomarkers).

The greater incidence of cancer globally, as well as the higher acceptance of cancer treatments in developing regions, the paradigm shift in healthcare from disease diagnosis to risk assessment or early diagnosis, and the increasing use of biomarkers in drug development, are all factors driving the market growth. Cancer is the second biggest cause of mortality worldwide, as per the World Health Organization (WHO) 2018 report, with an estimated 9.6 million deaths in 2018. Cancer is responsible for around 1 in every 6 deaths worldwide. 70% of these deaths occur in low and middle income countries. Biomarkers play a critical role in risk assessment, early diagnosis, and effective treatment monitoring; therefore, the market is likely to grow as the prevalence of many lifestyle illnesses rises.

The National Cancer Institute (NCI) invested in March 2016 to establish laboratories for biomarker and biomarker assay research for malignancies of the breast, prostate, lung, and genitourinary organs, as well as cancers with a high incidence rate. Mr. Liangren Li, an Auckland entrepreneur, and his family gave the University of Auckland a grant in April 2016 to perform cancer biomarker research. The money will be used to start the PROSPER project (Profiling of Oncology Patients in Clinical Care and Research).

COVID-19 Impact

The novel coronavirus (covid-19, sars-cov-2) was once assumed to be predominantly a respiratory disease, but as more individuals got the virus, it became obvious that it had a wide range of physiological effects. Covid-19 has an effect on the cardiovascular system and can create difficulties in the brain, kidney, and other organs in addition to the lungs. A multidisciplinary care team is frequently required for critical patients. COVID patients with comorbidities were also more likely to experience severe symptoms that necessitated hospitalization. Despite this, COVID patients with pre-existing cardiovascular problems have the highest fatality rate.

Market Growth Factors

Personalized medicine for cancer treatment
One of the primary factors expected to drive demand for cancer biomarkers is a paradigm shift toward personalized medicine for cancer therapy due to a lack of conventional diagnosis and treatment. Biomarkers are also becoming more important in personalized medicine, with applications in diagnosis, prognosis, and the selection of targeted therapy. Collaborations between various key industry companies and research institutes with the goal of developing novel cancer biomarkers for personalized treatment are also expected to boost market expansion over the forecast period.
The growing incidence of cancer
Companion diagnostics, tailored medications, and other disease diagnostics, such as disease risk assessment and drug research and development, all rely heavily on cancer biomarkers. One of the primary reasons likely to boost cancer biomarkers market growth during the upcoming years is the increased utilization of biomarkers in disease diagnosis. The rising global prevalence of cancer is driving the need for early disease detection, which is propelling the cancer biomarker market forward. According to the National Cancer Institute, 1,735,350 new cancer cases were reported in the United States in 2018.

Market Restraining Factors
Shortage of reimbursement policies for biomarker testing
Despite the rising global incidence of cancer and the increasing number of patients requiring diagnostic tests, the lack of reimbursement regulations for biomarker tests in emerging and industrialized nations is one issue restricting demand for these biomarkers. One of the most important concerns for service providers is sample collection, which is followed by sample access. These samples must be subjected to stringent quality control, and they must be maintained in the proper conditions to avoid loss. Various samples are also necessary for risk detection, screening, diagnosis, and monitoring.

Profiling Technologies Outlook
Based on Profiling Technologies, the market is segmented into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, and Cytogenetics. The imaging technologies segment garnered a significant revenue share in the cancer biomarker market in 2021. Imaging biomarkers (IBs) are important for the treatment of patients suffering from cancer. Clinical TNM stage, objective response, and left ventricular ejection fraction are all IBs utilized in cancer on a daily basis. Other biomarkers like CT, MRI, PET, and ultrasonography are widely employed in cancer research and medication development. By bridging ‘translational gaps’ through validation and qualification, new IBs can be produced as effective instruments for testing research ideas in clinical trials & research studies, or as clinical decision-making tools for use in healthcare.

Application Outlook
Based on Application, the market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Others. The diagnostics segment acquired the highest revenue share in the cancer biomarker market in 2021. The utilization of cancer biomarkers in drug discovery and development, as well as increased R&D on cancer biomarkers, are driving this segment’s growth.

Type Outlook
Based on Type, the market is segmented into Protein, Genetic, and Others. The genetic segment garnered a significant revenue share in the cancer biomarker market in 2021. This is due to its accuracy in predicting cancer stage, detecting cancer recurrence, and monitoring therapy success. Biomarkers can also be detected in non-invasively collected biofluids such as blood or serum, allowing for speedier cancer diagnosis, early detection, and screening. Additionally, cancer biomarkers can be used to improve understanding of efficacy, drug metabolism, pharmacological action, and safety by being subjected to dynamic modification.

Cancer Type Outlook
Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Thyroid Cancer, Melanoma & Leukemia, Kidney & Bladder Cancer, Non-Hodgkin’s Lymphoma, Prostate Cancer, and Others. The breast cancer segment acquired the highest revenue share in the cancer biomarker market in 2021.Breast cancer is more common than other types of cancer, such as prostate and stomach cancer. It took the lives of many people last year. Additionally, because oestrogen and progesterone growth hormones are always exposed to female breast cells, it is more popular among women than men. Obesity in females, on the other hand, plays a role in the progression of breast cancer cases. Obesity prevalence, on the other hand, varies greatly from country to country.

Regional Outlook Outlook
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The North American region acquired the largest revenue share in the cancer biomarker market in 2021. The expanding R&D on cancer biomarkers and rising technological breakthroughs in the development of cancer biomarkers are driving the growth of the North American cancer biomarkers market. The number of cancer patients in the United States has increased dramatically. According to the American Cancer Society, there were 1,735,350 new cancer cases identified and 609,640 cancer-related deaths in the United States in 2018. Lung cancer, breast cancer, colorectum cancer, cancer, bladder cancer, and skin cancer are the most frequent malignancies in the United States.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Agilent Technologies, Inc., and Merck & Co., Inc.

Strategies deployed in Cancer Biomarkers Market

Dec-2021: Hoffmann-La Roche introduced the research use only (RUO) of 3 new automated digital pathology algorithms, uPath ER (SP1), uPath Ki-67 (30-9), & uPath PR (1E2) image analysis. These analyses are for breast cancer images to produce actionable assessments of scanned slide images that are objective & reproducible, helping pathologists in the counting of these breast cancer markers.

Jul-2021: QIAGEN came into a partnership with Japan’s Sysmex Corporation for the development & commercialization of cancer companion diagnostics, which would improve both QIAGEN’s leadership in this field & Sysmex’s Plasma-Safe-SeqS technology for Next-generation sequencing (NGS). This partnership aimed to build collaborations with pharmaceutical companies for the development of drug treatments for cancer & promote early clinical adoption of ultra-sensitive liquid biopsy companion diagnostics.

Mar-2021: Hoffmann-La Roche released the DISCOVERY Green HRP kit 1. It is the overall collection of modular-based detection kits to identify & profile biomarkers and cell populations in tissue-based research. The innovative DISCOVERY chromogens have translucent properties that allow researchers to analyze the co-localization of various biomarkers through the spatial overlapping of two signals in the terms of tissue.

Oct-2020: Agilent Technologies joined hands with InterVenn, a biotechnology company. This collaboration aimed at the diseases common in Southeast Asia, and the premises for this development work would be at InterVenn Malaysia’s laboratory located at Technology Park Malaysia in KL.

Sep-2020: Thermo Fisher Scientific joined hands with AstraZenca, a big name in pharmaceutical and the University of Nebraska Medical Center (UNMC). This collaboration aimed to enhance unique solutions to deal with requirements that weren’t met before in clinical biomarker discovery. These solutions would assist streamline the transition from biomarker research to clinical implementation, making the path for new opportunities in precision medicine.

Mar-2020: Thermo Fisher Scientific came into an agreement with Janessen Biotech, one of the subsidiaries of Janssen Pharmaceutical Companies of Johnson & Johnson. This agreement aimed to co-develop a companion diagnostic (CDx) in oncology. The CDx would aid the clinical trial enrollment globally. In this agreement, Thermo Fisher Scientific would join hands with Janssen Research & Development scientists to validate the multiple biomarkers for use with Thermo Fisher’s Oncomine Dx Target Test, which would be utilized to detect variant-positive patients for enrollment into clinical trials focused on non-small cell lung cancer (NSCLC). In addition, indications in oncology may follow as part of the agreement.

May-2019: QIAGEN introduced the therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit). This product would help in detecting breast cancer patients eligible for treatment with PIQRAY (alpelisib), a newly approved therapy developed & marketed by Novartis. The therascreenPIK3CA Kit is the first companion diagnostic assay to receive premarket approval from the U.S. Food and Drug Administration (FDA) for use in any cancer indication for detection of activating mutations in the PIK3CA gene. It is the first FDA-approved assay for guiding treatment decisions in breast cancer with the use of plasma specimens as a liquid biopsy.

Dec-2018: Hoffman-La Roche came into partnership with Merck, an American multinational pharmaceutical company. This partnership aimed to develop a pan-cancer companion diagnostic to detect advanced solid tumor patients who need anti-PD-1 therapy. Both the companies would broaden the usage of this panel to comprise the identification of patients with solid tumors who can undergo immunotherapy. The new IHC companion diagnostic is being developed for usage on the Roche BenchMark ULTRA instrument. In addition, Roche looked for FDA approval to use the biomarker panel as a standardized predictive testing option for dMMR.

Apr-2018: BioMerieux signed an agreement of acquisition with Astute Medical, a company focused on enhancing the diagnosis of high-risk medical conditions & diseases through the identification & validation of protein biomarkers. This acquisition aimed to develop & market the NEPHROCHECK test for the VIDAS automated immunoassay system. Since 2017, bioMérieux has been a licensed distributor with Astute for the NEPHROCHECK test on the Astute140 Meter in the US.
Scope of the Study

Market Segments covered in the Report:

By Profiling Technologies
• Omics Technologies
• Imaging Technologies
• Immunoassay
• Bioinformatics
• Cytogenetics

By Application
• Diagnostics
• Research & Development
• Prognostics
• Risk Assessment
• Others

By Type
• Protein
• Genetic
• Others

By Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Thyroid Cancer
• Melanoma & Leukemia
• Kidney & Bladder Cancer
• Non-Hodgkin’s Lymphoma
• Prostate Cancer
• Others

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• BioMérieux S.A.
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Abbott Laboratories
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• Agilent Technologies, Inc.
• Merck & Co., Inc.

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

*** レポート目次(コンテンツ)***

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Cancer Biomarkers Market, by Profiling Technologies
1.4.2 Global Cancer Biomarkers Market, by Application
1.4.3 Global Cancer Biomarkers Market, by Type
1.4.4 Global Cancer Biomarkers Market, by Cancer Type
1.4.5 Global Cancer Biomarkers Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Cancer Biomarkers Market
Chapter 4. Global Cancer Biomarkers Market by Profiling Technologies
4.1 Global Omics Technologies Market by Region
4.2 Global Imaging Technologies Market by Region
4.3 Global Immunoassay Market by Region
4.4 Global Bioinformatics Market by Region
4.5 Global Cytogenetics Market by Region
Chapter 5. Global Cancer Biomarkers Market by Application
5.1 Global Diagnostics Market by Region
5.2 Global Research & Development Market by Region
5.3 Global Prognostics Market by Region
5.4 Global Risk Assessment Market by Region
5.5 Global Others Market by Region
Chapter 6. Global Cancer Biomarkers Market by Type
6.1 Global Protein Market by Region
6.2 Global Genetic Market by Region
6.3 Global Others Market by Region
Chapter 7. Global Cancer Biomarkers Market by Cancer Type
7.1 Global Breast Cancer Market by Region
7.2 Global Lung Cancer Market by Region
7.3 Global Colorectal Cancer Market by Region
7.4 Global Thyroid Cancer Market by Region
7.5 Global Melanoma & Leukemia Market by Region
7.6 Global Kidney & Bladder Cancer Market by Region
7.7 Global Non-Hodgkin’s Lymphoma Market by Region
7.8 Global Prostate Cancer Market by Region
7.9 Global Others Market by Region
Chapter 8. Global Cancer Biomarkers Market by Region
8.1 North America Cancer Biomarkers Market
8.1.1 North America Cancer Biomarkers Market by Profiling Technologies
8.1.1.1 North America Omics Technologies Market by Country
8.1.1.2 North America Imaging Technologies Market by Country
8.1.1.3 North America Immunoassay Market by Country
8.1.1.4 North America Bioinformatics Market by Country
8.1.1.5 North America Cytogenetics Market by Country
8.1.2 North America Cancer Biomarkers Market by Application
8.1.2.1 North America Diagnostics Market by Country
8.1.2.2 North America Research & Development Market by Country
8.1.2.3 North America Prognostics Market by Country
8.1.2.4 North America Risk Assessment Market by Country
8.1.2.5 North America Others Market by Country
8.1.3 North America Cancer Biomarkers Market by Type
8.1.3.1 North America Protein Market by Country
8.1.3.2 North America Genetic Market by Country
8.1.3.3 North America Others Market by Country
8.1.4 North America Cancer Biomarkers Market by Cancer Type
8.1.4.1 North America Breast Cancer Market by Country
8.1.4.2 North America Lung Cancer Market by Country
8.1.4.3 North America Colorectal Cancer Market by Country
8.1.4.4 North America Thyroid Cancer Market by Country
8.1.4.5 North America Melanoma & Leukemia Market by Country
8.1.4.6 North America Kidney & Bladder Cancer Market by Country
8.1.4.7 North America Non-Hodgkin’s Lymphoma Market by Country
8.1.4.8 North America Prostate Cancer Market by Country
8.1.4.9 North America Others Market by Country
8.1.5 North America Cancer Biomarkers Market by Country
8.1.5.1 US Cancer Biomarkers Market
8.1.5.1.1 US Cancer Biomarkers Market by Profiling Technologies
8.1.5.1.2 US Cancer Biomarkers Market by Application
8.1.5.1.3 US Cancer Biomarkers Market by Type
8.1.5.1.4 US Cancer Biomarkers Market by Cancer Type
8.1.5.2 Canada Cancer Biomarkers Market
8.1.5.2.1 Canada Cancer Biomarkers Market by Profiling Technologies
8.1.5.2.2 Canada Cancer Biomarkers Market by Application
8.1.5.2.3 Canada Cancer Biomarkers Market by Type
8.1.5.2.4 Canada Cancer Biomarkers Market by Cancer Type
8.1.5.3 Mexico Cancer Biomarkers Market
8.1.5.3.1 Mexico Cancer Biomarkers Market by Profiling Technologies
8.1.5.3.2 Mexico Cancer Biomarkers Market by Application
8.1.5.3.3 Mexico Cancer Biomarkers Market by Type
8.1.5.3.4 Mexico Cancer Biomarkers Market by Cancer Type
8.1.5.4 Rest of North America Cancer Biomarkers Market
8.1.5.4.1 Rest of North America Cancer Biomarkers Market by Profiling Technologies
8.1.5.4.2 Rest of North America Cancer Biomarkers Market by Application
8.1.5.4.3 Rest of North America Cancer Biomarkers Market by Type
8.1.5.4.4 Rest of North America Cancer Biomarkers Market by Cancer Type
8.2 Europe Cancer Biomarkers Market
8.2.1 Europe Cancer Biomarkers Market by Profiling Technologies
8.2.1.1 Europe Omics Technologies Market by Country
8.2.1.2 Europe Imaging Technologies Market by Country
8.2.1.3 Europe Immunoassay Market by Country
8.2.1.4 Europe Bioinformatics Market by Country
8.2.1.5 Europe Cytogenetics Market by Country
8.2.2 Europe Cancer Biomarkers Market by Application
8.2.2.1 Europe Diagnostics Market by Country
8.2.2.2 Europe Research & Development Market by Country
8.2.2.3 Europe Prognostics Market by Country
8.2.2.4 Europe Risk Assessment Market by Country
8.2.2.5 Europe Others Market by Country
8.2.3 Europe Cancer Biomarkers Market by Type
8.2.3.1 Europe Protein Market by Country
8.2.3.2 Europe Genetic Market by Country
8.2.3.3 Europe Others Market by Country
8.2.4 Europe Cancer Biomarkers Market by Cancer Type
8.2.4.1 Europe Breast Cancer Market by Country
8.2.4.2 Europe Lung Cancer Market by Country
8.2.4.3 Europe Colorectal Cancer Market by Country
8.2.4.4 Europe Thyroid Cancer Market by Country
8.2.4.5 Europe Melanoma & Leukemia Market by Country
8.2.4.6 Europe Kidney & Bladder Cancer Market by Country
8.2.4.7 Europe Non-Hodgkin’s Lymphoma Market by Country
8.2.4.8 Europe Prostate Cancer Market by Country
8.2.4.9 Europe Others Market by Country
8.2.5 Europe Cancer Biomarkers Market by Country
8.2.5.1 Germany Cancer Biomarkers Market
8.2.5.1.1 Germany Cancer Biomarkers Market by Profiling Technologies
8.2.5.1.2 Germany Cancer Biomarkers Market by Application
8.2.5.1.3 Germany Cancer Biomarkers Market by Type
8.2.5.1.4 Germany Cancer Biomarkers Market by Cancer Type
8.2.5.2 UK Cancer Biomarkers Market
8.2.5.2.1 UK Cancer Biomarkers Market by Profiling Technologies
8.2.5.2.2 UK Cancer Biomarkers Market by Application
8.2.5.2.3 UK Cancer Biomarkers Market by Type
8.2.5.2.4 UK Cancer Biomarkers Market by Cancer Type
8.2.5.3 France Cancer Biomarkers Market
8.2.5.3.1 France Cancer Biomarkers Market by Profiling Technologies
8.2.5.3.2 France Cancer Biomarkers Market by Application
8.2.5.3.3 France Cancer Biomarkers Market by Type
8.2.5.3.4 France Cancer Biomarkers Market by Cancer Type
8.2.5.4 Russia Cancer Biomarkers Market
8.2.5.4.1 Russia Cancer Biomarkers Market by Profiling Technologies
8.2.5.4.2 Russia Cancer Biomarkers Market by Application
8.2.5.4.3 Russia Cancer Biomarkers Market by Type
8.2.5.4.4 Russia Cancer Biomarkers Market by Cancer Type
8.2.5.5 Spain Cancer Biomarkers Market
8.2.5.5.1 Spain Cancer Biomarkers Market by Profiling Technologies
8.2.5.5.2 Spain Cancer Biomarkers Market by Application
8.2.5.5.3 Spain Cancer Biomarkers Market by Type
8.2.5.5.4 Spain Cancer Biomarkers Market by Cancer Type
8.2.5.6 Italy Cancer Biomarkers Market
8.2.5.6.1 Italy Cancer Biomarkers Market by Profiling Technologies
8.2.5.6.2 Italy Cancer Biomarkers Market by Application
8.2.5.6.3 Italy Cancer Biomarkers Market by Type
8.2.5.6.4 Italy Cancer Biomarkers Market by Cancer Type
8.2.5.7 Rest of Europe Cancer Biomarkers Market
8.2.5.7.1 Rest of Europe Cancer Biomarkers Market by Profiling Technologies
8.2.5.7.2 Rest of Europe Cancer Biomarkers Market by Application
8.2.5.7.3 Rest of Europe Cancer Biomarkers Market by Type
8.2.5.7.4 Rest of Europe Cancer Biomarkers Market by Cancer Type
8.3 Asia Pacific Cancer Biomarkers Market
8.3.1 Asia Pacific Cancer Biomarkers Market by Profiling Technologies
8.3.1.1 Asia Pacific Omics Technologies Market by Country
8.3.1.2 Asia Pacific Imaging Technologies Market by Country
8.3.1.3 Asia Pacific Immunoassay Market by Country
8.3.1.4 Asia Pacific Bioinformatics Market by Country
8.3.1.5 Asia Pacific Cytogenetics Market by Country
8.3.2 Asia Pacific Cancer Biomarkers Market by Application
8.3.2.1 Asia Pacific Diagnostics Market by Country
8.3.2.2 Asia Pacific Research & Development Market by Country
8.3.2.3 Asia Pacific Prognostics Market by Country
8.3.2.4 Asia Pacific Risk Assessment Market by Country
8.3.2.5 Asia Pacific Others Market by Country
8.3.3 Asia Pacific Cancer Biomarkers Market by Type
8.3.3.1 Asia Pacific Protein Market by Country
8.3.3.2 Asia Pacific Genetic Market by Country
8.3.3.3 Asia Pacific Others Market by Country
8.3.4 Asia Pacific Cancer Biomarkers Market by Cancer Type
8.3.4.1 Asia Pacific Breast Cancer Market by Country
8.3.4.2 Asia Pacific Lung Cancer Market by Country
8.3.4.3 Asia Pacific Colorectal Cancer Market by Country
8.3.4.4 Asia Pacific Thyroid Cancer Market by Country
8.3.4.5 Asia Pacific Melanoma & Leukemia Market by Country
8.3.4.6 Asia Pacific Kidney & Bladder Cancer Market by Country
8.3.4.7 Asia Pacific Non-Hodgkin’s Lymphoma Market by Country
8.3.4.8 Asia Pacific Prostate Cancer Market by Country
8.3.4.9 Asia Pacific Others Market by Country
8.3.5 Asia Pacific Cancer Biomarkers Market by Country
8.3.5.1 China Cancer Biomarkers Market
8.3.5.1.1 China Cancer Biomarkers Market by Profiling Technologies
8.3.5.1.2 China Cancer Biomarkers Market by Application
8.3.5.1.3 China Cancer Biomarkers Market by Type
8.3.5.1.4 China Cancer Biomarkers Market by Cancer Type
8.3.5.2 Japan Cancer Biomarkers Market
8.3.5.2.1 Japan Cancer Biomarkers Market by Profiling Technologies
8.3.5.2.2 Japan Cancer Biomarkers Market by Application
8.3.5.2.3 Japan Cancer Biomarkers Market by Type
8.3.5.2.4 Japan Cancer Biomarkers Market by Cancer Type
8.3.5.3 India Cancer Biomarkers Market
8.3.5.3.1 India Cancer Biomarkers Market by Profiling Technologies
8.3.5.3.2 India Cancer Biomarkers Market by Application
8.3.5.3.3 India Cancer Biomarkers Market by Type
8.3.5.3.4 India Cancer Biomarkers Market by Cancer Type
8.3.5.4 South Korea Cancer Biomarkers Market
8.3.5.4.1 South Korea Cancer Biomarkers Market by Profiling Technologies
8.3.5.4.2 South Korea Cancer Biomarkers Market by Application
8.3.5.4.3 South Korea Cancer Biomarkers Market by Type
8.3.5.4.4 South Korea Cancer Biomarkers Market by Cancer Type
8.3.5.5 Singapore Cancer Biomarkers Market
8.3.5.5.1 Singapore Cancer Biomarkers Market by Profiling Technologies
8.3.5.5.2 Singapore Cancer Biomarkers Market by Application
8.3.5.5.3 Singapore Cancer Biomarkers Market by Type
8.3.5.5.4 Singapore Cancer Biomarkers Market by Cancer Type
8.3.5.6 Malaysia Cancer Biomarkers Market
8.3.5.6.1 Malaysia Cancer Biomarkers Market by Profiling Technologies
8.3.5.6.2 Malaysia Cancer Biomarkers Market by Application
8.3.5.6.3 Malaysia Cancer Biomarkers Market by Type
8.3.5.6.4 Malaysia Cancer Biomarkers Market by Cancer Type
8.3.5.7 Rest of Asia Pacific Cancer Biomarkers Market
8.3.5.7.1 Rest of Asia Pacific Cancer Biomarkers Market by Profiling Technologies
8.3.5.7.2 Rest of Asia Pacific Cancer Biomarkers Market by Application
8.3.5.7.3 Rest of Asia Pacific Cancer Biomarkers Market by Type
8.3.5.7.4 Rest of Asia Pacific Cancer Biomarkers Market by Cancer Type
8.4 LAMEA Cancer Biomarkers Market
8.4.1 LAMEA Cancer Biomarkers Market by Profiling Technologies
8.4.1.1 LAMEA Omics Technologies Market by Country
8.4.1.2 LAMEA Imaging Technologies Market by Country
8.4.1.3 LAMEA Immunoassay Market by Country
8.4.1.4 LAMEA Bioinformatics Market by Country
8.4.1.5 LAMEA Cytogenetics Market by Country
8.4.2 LAMEA Cancer Biomarkers Market by Application
8.4.2.1 LAMEA Diagnostics Market by Country
8.4.2.2 LAMEA Research & Development Market by Country
8.4.2.3 LAMEA Prognostics Market by Country
8.4.2.4 LAMEA Risk Assessment Market by Country
8.4.2.5 LAMEA Others Market by Country
8.4.3 LAMEA Cancer Biomarkers Market by Type
8.4.3.1 LAMEA Protein Market by Country
8.4.3.2 LAMEA Genetic Market by Country
8.4.3.3 LAMEA Others Market by Country
8.4.4 LAMEA Cancer Biomarkers Market by Cancer Type
8.4.4.1 LAMEA Breast Cancer Market by Country
8.4.4.2 LAMEA Lung Cancer Market by Country
8.4.4.3 LAMEA Colorectal Cancer Market by Country
8.4.4.4 LAMEA Thyroid Cancer Market by Country
8.4.4.5 LAMEA Melanoma & Leukemia Market by Country
8.4.4.6 LAMEA Kidney & Bladder Cancer Market by Country
8.4.4.7 LAMEA Non-Hodgkin’s Lymphoma Market by Country
8.4.4.8 LAMEA Prostate Cancer Market by Country
8.4.4.9 LAMEA Others Market by Country
8.4.5 LAMEA Cancer Biomarkers Market by Country
8.4.5.1 Brazil Cancer Biomarkers Market
8.4.5.1.1 Brazil Cancer Biomarkers Market by Profiling Technologies
8.4.5.1.2 Brazil Cancer Biomarkers Market by Application
8.4.5.1.3 Brazil Cancer Biomarkers Market by Type
8.4.5.1.4 Brazil Cancer Biomarkers Market by Cancer Type
8.4.5.2 Argentina Cancer Biomarkers Market
8.4.5.2.1 Argentina Cancer Biomarkers Market by Profiling Technologies
8.4.5.2.2 Argentina Cancer Biomarkers Market by Application
8.4.5.2.3 Argentina Cancer Biomarkers Market by Type
8.4.5.2.4 Argentina Cancer Biomarkers Market by Cancer Type
8.4.5.3 UAE Cancer Biomarkers Market
8.4.5.3.1 UAE Cancer Biomarkers Market by Profiling Technologies
8.4.5.3.2 UAE Cancer Biomarkers Market by Application
8.4.5.3.3 UAE Cancer Biomarkers Market by Type
8.4.5.3.4 UAE Cancer Biomarkers Market by Cancer Type
8.4.5.4 Saudi Arabia Cancer Biomarkers Market
8.4.5.4.1 Saudi Arabia Cancer Biomarkers Market by Profiling Technologies
8.4.5.4.2 Saudi Arabia Cancer Biomarkers Market by Application
8.4.5.4.3 Saudi Arabia Cancer Biomarkers Market by Type
8.4.5.4.4 Saudi Arabia Cancer Biomarkers Market by Cancer Type
8.4.5.5 South Africa Cancer Biomarkers Market
8.4.5.5.1 South Africa Cancer Biomarkers Market by Profiling Technologies
8.4.5.5.2 South Africa Cancer Biomarkers Market by Application
8.4.5.5.3 South Africa Cancer Biomarkers Market by Type
8.4.5.5.4 South Africa Cancer Biomarkers Market by Cancer Type
8.4.5.6 Nigeria Cancer Biomarkers Market
8.4.5.6.1 Nigeria Cancer Biomarkers Market by Profiling Technologies
8.4.5.6.2 Nigeria Cancer Biomarkers Market by Application
8.4.5.6.3 Nigeria Cancer Biomarkers Market by Type
8.4.5.6.4 Nigeria Cancer Biomarkers Market by Cancer Type
8.4.5.7 Rest of LAMEA Cancer Biomarkers Market
8.4.5.7.1 Rest of LAMEA Cancer Biomarkers Market by Profiling Technologies
8.4.5.7.2 Rest of LAMEA Cancer Biomarkers Market by Application
8.4.5.7.3 Rest of LAMEA Cancer Biomarkers Market by Type
8.4.5.7.4 Rest of LAMEA Cancer Biomarkers Market by Cancer Type
Chapter 9. Company Profiles
9.1 BioMérieux S.A.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.3 Becton, Dickinson and Company
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Abbott Laboratories
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.5 Thermo Fisher Scientific, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.6 SWOT Analysis
9.6 Illumina, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.7 Bio-Rad laboratories, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Qiagen N.V.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Product Launches and Product Expansions:
9.9 Agilent Technologies, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.10. Merck & Co., Inc. (Merck Millipore)
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(KBV22JL116 )"がんバイオマーカーのグローバル市場2021~2028:オミックス技術、イメージング技術、イムノアッセイ、バイオインフォマティクス、その他" (英文:Global Cancer Biomarkers Market Size, Share & Industry Trends Analysis Report By Profiling Technologies, By Application, By Type, By Cancer Type, By Regional Outlook and Forecast, 2022 - 2028)はKBV Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。